Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Wednesday, November 25, 2009, 12:57PM ET - U.S. Markets close in 3 hours and 3 minutes. Dow Up 0.18% Nasdaq Up 0.22%
King Pharmaceuticals Inc. (KG)At 12:42PM ET: 12.08   0.00 (0.00%)  
MORE ON KG
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
King Pharmaceuticals Inc.
501 Fifth Street
Bristol, TN 37620
United States - Map
Phone: 423-989-8000
Fax: 423-274-8677
Web Site: http://www.kingpharm.com

DETAILS 
Index Membership:S&P 500
S&P 1500 Super Comp
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:3,381

BUSINESS SUMMARY 
King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. The company’s branded prescription pharmaceuticals include neuroscience products, such as Skelaxin, Avinza, and Sonata; hospital products, including Thrombin-JMI and Synercid; acute care products that comprise Bicillin and Intal; and legacy products consisting of Altace, Levoxyl, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. Its animal health business focuses on medicated feed additives (MFAs) and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets. The company also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. King Pharmaceuticals also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan and Adenocard. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. Adenocard is a sterile solution of adenosine administered intravenously in emergency situations to convert certain irregular heart rhythms to normal sinus rhythms. It distributes its branded pharmaceutical products through wholesale pharmaceutical distributors and a sales force. King Pharmaceuticals was founded in 1993 and is headquartered in Bristol, Tennessee.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on King Pharmaceuticals Inc.


    CORPORATE GOVERNANCE 
    King Pharmaceuticals Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 28.5% of S&P 500 companies and 92.4% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Mr. Brian A. Markison , 49
    Chairman, Chief Exec. Officer, Pres and Chairman of Risk Committee
    N/A N/A
    Mr. Joseph Squicciarino , 52
    Chief Financial Officer and Principal Accounting Officer
    N/A N/A
    Mr. Eric J. Bruce , 52
    Pres of Alpharma Animal Health
    N/A N/A
    Mr. Stephen J. Andrzejewski , 43
    Chief Commercial Officer
    N/A N/A
    Mr. James W. Elrod , 48
    Chief Legal Officer and Corp. Sec.
    $ 690.00KN/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis